Abstract B080: AB-1015, an Integrated Circuit T (ICT) cell therapy containing an ALPG/MSLN logic gate and FAS/PTPN2 shRNA-miR, for the treatment of ovarian cancer

View Full Paper

Ask AI

Bookmark

AB-1015 integrated circuit T cell therapy selectively destroys ovarian cancer cells displaying both ALPG and MSLN target antigens.
AB-1015 showed over a 100-fold increase in IFNg production during in vitro co-culture assays with dual-antigen targets versus single antigen.
Preclinical assessment using dual-flank and intraperitoneal xenograft models verified targeted tumor reduction and resistance to FASL suppression.

Discussion

No takes yet. Share an insight, caveat, or question.

Preclinical study demonstrates selective antitumor activity of AB-1015 in ovarian cancer models, highlighting reduced off-tumor toxicity.

Feng et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark